Advice
Following a resubmission
bemiparin (Zibor) is not recommended for use within NHS Scotland for the prevention of thromboembolic events in patients undergoing orthopaedic surgery.
Bemiparin was associated with a lower incidence of thromboembolic complications than unfractionated heparin and was non-inferior to another low molecular weight heparin.
The manufacturer did not present a sufficiently robust economic analysis to gain acceptance by SMC.
Download detailed advice61KB (PDF)
Medicine details
- Medicine name:
- bemiparin 3500 IU in 0.2ml injection for sub-cutaneous administration (Zibor)
- SMC ID:
- 204/05
- Indication:
- Prevention of thromboembolic disease in patient undergoing orthopaedic surgery
- Pharmaceutical company
- Pan Quimica Farmaceutica S.A.
- BNF chapter
- Cardiovascular system
- Submission type
- Resubmission
- Status
- Not recommended
- Date advice published
- 09 July 2007